Status:
COMPLETED
Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects
Lead Sponsor:
Amgen
Conditions:
Dyslipidemia
Eligibility:
All Genders
40-85 years
Phase:
PHASE3
Brief Summary
This study evaluated change over time in neurocognitive testing in patients receiving statin therapy in combination with evolocumab (AMG 145), compared with patients receiving statin therapy in combin...
Detailed Description
Participants who were enrolled in study 20110118 (FOURIER; NCT01764633) at select sites in select countries (selected based on study start-up timelines) were invited to participate in this cognitive f...
Eligibility Criteria
Inclusion
- Randomized into Study 20110118 (FOURIER; NCT01764633)
Exclusion
- Current or known past diagnosis of dementia or mild cognitive impairment (MCI)
Key Trial Info
Start Date :
September 10 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 11 2016
Estimated Enrollment :
1974 Patients enrolled
Trial Details
Trial ID
NCT02207634
Start Date
September 10 2014
End Date
November 11 2016
Last Update
January 16 2018
Active Locations (416)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Birmingham, Alabama, United States, 35294
2
Research Site
Huntsville, Alabama, United States, 35801
3
Research Site
Mobile, Alabama, United States, 36608
4
Research Site
Glendale, Arizona, United States, 85306